Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Daniel V.T. Catenacci(University of Illinois Chicago), Niall C. Tebbutt(Austin Health), Ірина Давиденко(Specialized Clinical Psychiatric Hospital No. 1), André M. Murad(Hospital das Clínicas da Universidade Federal de Minas Gerais), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), David H. Ilson(Memorial Sloan Kettering Cancer Center), Sergei Tjulandin(Russian Cancer Research Center NN Blokhin), Evengy Gotovkin(Ivanovo State Medical Academy), Bogusława Karaszewska, Igor Bondarenko(Dnipropetrovsk State Medical Academy), Mohamedtaki Abdulaziz Tejani(University of Rochester Medical Center), Anghel Adrian Udrea, Mustapha Tehfé(Hôpital Notre-Dame), Ferdinando De Vita(University of Campania "Luigi Vanvitelli"), Cheryl Turkington(Amgen (United Kingdom)), Rui Tang(Amgen (United States)), Agnes Ang(Amgen (United States)), Yilong Zhang(Amgen (United States)), Tien Hoang(Amgen (United States)), Roger Sidhu(Amgen (United States)), David Cunningham(Royal Marsden Hospital)
Cited by 343Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis